Overview
12th Annual Linda Morgante MS Nurse Leadership Program
Registration is closed for this activity.
The 12th Annual Linda Morgante MS Nurse Leadership Program will be held virtually on Saturday, June 26, 2021. This virtual meeting will explore the essential role of nurses in monitoring symptoms, evaluating medication changes, managing physical limitations, and addressing the disease’s psychosocial implications assisting MS patients in navigating their MS journey. Linda Morgante worked tirelessly as an MS nurse and touched the lives of thousands of physicians, nurses and patients and their families. Linda inspired her students to strive for excellence in nursing and this program is named after her legacy. This program will feature didactic presentations, patient case mentoring pods, office hours for faculty to reinforce key points, engage in Q&A, and discuss current challenges and frame opportunities in professional development.
This activity is intended for nurses and advanced practice clinicians who manage patients with multiple sclerosis (MS).
There are now a staggering 17 approved disease-modifying therapies for managing MS. Treatment selection remains challenging given a lack of guidance and disease heterogeneity. Additionally, long-term medication compliance persists as a barrier to optimal care. Nurse-targeted education is critical secondary to the increased need for outcome-driven care, which encompasses not only diagnosis, but also adverse event and symptom management as well as care coordination. This virtual program provides MS nurses access to the latest insights and strategies to best apply to their own practice, ultimately ensuring comprehensive patient care and the best possible outcomes.
Upon completion of this activity, participants will be able to:
- Apply evidence-based diagnostic and assessment approaches for evaluating disease activity in the brain and spinal cord to develop individualized treatment plans in patients with MS
- Improve patient outcomes and adherence to therapy by identifying, assessing, and managing emerging MS-related symptoms and DMT-related adverse events.
- Employ treat-to-target strategies and precision medicine to improve patient long-term outcomes
Provided by the Academy for Continued Healthcare Learning and Annenberg Center for Health Sciences at Eisenhower.
Supported by educational grants from Bristol-Myers Squibb, EMD Serono, Inc., Greenwich Biosciences, Inc., Novartis Pharmaceuticals Company and Sanofi Genzyme.
- Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
- Compatible with Windows PC and MAC (256 MB of RAM or higher)
- Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
- Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
- Adobe Reader to print certificate. Click here to download Adobe Reader for free.
- Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run
- Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Colleen Harris, MN, NP, MSCN, MSCS
Nurse Practitioner
University of Calgary MS Clinic
Calgary, Alberta, Canada
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Chicago Medical Center
Maywood, Illinois
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN, MSCN
Adjunct Assistant Professor
Co-Director Research/EBP/QI
Mount Sinai Medical Center
Assistant Professor
Researcher, Hunter College
Bellevue School of Nursing
New York, New York
Nurse Practitioner
University of Calgary MS Clinic
Calgary, Alberta, Canada
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Chicago Medical Center
Maywood, Illinois
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN, MSCN
Adjunct Assistant Professor
Co-Director Research/EBP/QI
Mount Sinai Medical Center
Assistant Professor
Researcher, Hunter College
Bellevue School of Nursing
New York, New York
Cheryl Blaschuk, MSN
Nurse Practitioner
Medical College of Wisconsin
Comprehensive Multiple Sclerosis Clinic
Froedtert & Medical College of Wisconsin
Wauwatosa, Wisconsin
Constance Easterling, MSN, ARNP, MSCN
Advanced Practice Registered Nurse
Research consultant
MS Care Center
Neurological Services of Orlando
Orlando, Florida
June Halper, MSN, APN-C, MSCN, FAAN
Chief Executive Officer
Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses
Hackensack, New Jersey
Michelle Keating, RN, MSCN
MS Nurse Consultant
St. Louis, Missouri
Beverly Layton, RN, CCRC, MSCN
MS Nurse Consultant
Birmingham, Alabama
Lynn McEwan, NP, MScN, CNN(c), MSCN
London Health Sciences Centre-University Hospital
London, Ontario Canada
Marie Namey APRN, MSCN
MS Nurse Consultant
Recently retired from Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research
Cleveland, Ohio
Annenberg Center and ACHL requires that the faculty participating in a CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CE activity.
The following financial relationships have been provided:
Colleen Harris, MN, NP (Chair)
Consulting Agreements: BMS; EMD Serono; Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Consulting Agreements: Alexion; Biogen; EMD Serono; Genentech; Genzyme; Horizon; Janssen; Mallinckrodt; Novartis; Roche
Board Member: CMSC; IOMSN
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN, MSCN
Publication grant: EMD Serono; Greenwich Biosciences
Consulting Agreements: Biogen
Advisory Board: Biogen; Genentech; Greenwich Biosciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: My discussion may include off label treatments for the care of MS.
Beverly Layton, RN, CCRC, MSCN
Consulting Agreements: Banner Life Sciences; Biogen; Novartis; Sanofi Genzyme
Speakers' Bureau: Sanofi Genzyme
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Lynn McEwan, NP, MScN, CNN(c), MSCN
Consulting Agreements: BMS; EMD Serono; Novartis; Roche; Sanofi Genzyme
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Marie Namey APRN, MSCN
Consulting Agreements: Biogen; EMD Serono; Genentech; Novartis; Sanofi; Viela Bio
Speakers' Bureau: Biogen; Genentech; Novartis; Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The following faculty have no relevant financial relationships to disclose, and will not be discussing off-label, investigational, or experimental drug use:
Cheryl Blaschuk, MSN
Constance Easterling, MSN, ARNP, MSCN
June Halper, MSN, APN-C, MSCN, FAAN
Michelle Keating, RN, MSCN
ACHL and Annenberg Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ANCC Accreditation Program. Recommendations involving clinical medicine in a continuing education (CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers’ prescribing information for these products. Annenberg and ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to complete the pretest, participate in the live virtual activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katie Hacias at khacias@achlcme.org
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 5.0 contact hours, which includes 1.25 pharmacology hours, may be earned for successful completion of this activity.